source
- Summit and Akeso sharpen case for ivonescimab with new Western dataSummit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…
- Dyne Therapeutics receives early 2027 FDA decision date for Duchenne therapy, analysts anticipate smooth reviewDyne Therapeutics' investigational Duchenne muscular dystrophy therapy, zeleciment rostudirsen, has had its BLA accepted by the FDA with a target action date of Jan 21, 2027. Analysts at Oppenheim…